Canadian Alliance for Healthy Hearts and Minds

Cardiac, vascular, and cognitive dysfunction have a strong impact on the quality of life, longevity and health care costs, in Canada and globally. Cardiovascular risk factors account for up to half of the attributable risk for dementia, mediated in large part by difficult to detect microvascular disease of the brain. In this study the investigators will try to understand the role of the societal structure, nutrition, access to health services, and other socio-environmental and contextual factors on cardiovascular risk factors, subclinical disease and clinical cardiovascular events at the individual and population levels. We will try to identify markers for early subclinical dysfunction in the brain, vessels, heart and abdomen using magnetic resonance imaging and investigate the associations with contextual and individual determinants of these markers, as well as to assess the predictive value of novel markers of subclinical dysfunction on the development of clinical cardiovascular events.

Inclusion criteria

• Informed Consent Form (ICF) was discussed, understood and signed by the participant
• Participant is between ages 35 and 69 (inclusively) at time of screening
• The participant is willing to undergo an MRI scan and all other required study procedures

Exclusion criteria

• Participant has a known acute disease or condition that is considered serious in the investigator's opinion
• Participant is claustrophobic and/or is known to suffer from moderate to severe anxiety during MRI scans or similar procedures
• Participant is obese and/or exceeds equipment weight limit and/or circumference of the MRI portal at this of screening
• Participant has any kind of metallic device that would contra-indicate Magnetic Resonance Imaging (MRI) (e.g. pacemakers, defibrillator, vascular clips, drug pumps, implant(s), or any other foreign bodies)
• Participant has an extensive tattoo covering a large part of their chest or head
• Female participants that are currently pregnant (confirmed or uncertain).
• Participants receiving Gadovist® only - Female participants that are currently breastfeeding.
• Participants receiving Gadovist® only - Participant has a known hypersensitivity to gadolinium-based contrast agents
• Participants receiving Gadovist® only - Participant has a known allergy or severe reaction to any contrast agent typically used in MRI procedures
• Participants receiving Gadovist® only - Participant has known renal or hepatic impairment of any intensity or any other kidney/liver disease or has recently undergone kidney/liver transplant
• Participants receiving Gadovist® only - Participant has a known glomerular filtration rate (eGFR or GFR) of 30 mL/min or less
• Participants receiving Gadovist® only - Participant has taken part in a clinical research study or clinical study within 30 days prior to enrollment in this study, and/or received contrast agent within 72 hours prior to the study MRI